50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs.”In use 2003 – now·1 sighting·SEC Form 10-K/A, filed 2003-05-0890% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0775% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2973% match
“Our mission is to discover or acquire novel therapeutic product candidates targeting unmet medical needs in attractive specialty markets.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-03-1572% match
“Our mission is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-02-2871% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1971% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1570% match
“Our mission is to address the unmet medical need associated with vector-borne diseases through the development and commercialization of new small molecule therapeutics, focusing on synthetic drugs (made by chemists in labs, excluding biologics) with good safety profiles based on prior clinical studies, in order to reduce cost, risk, and capitalize on existing research.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3070% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0769% match
“Our mission is to develop and commercialize first-in-class medicines based on novel targets to improve patients’ lives.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-03-2469% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1069% match
“Our mission is to develop novel therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-03-2869% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1369% match
“Our mission is to discover and develop novel therapeutic drugs to treat diseases and disorders for which there are no adequate therapies or for which a new drug would represent a significant advancement over the current therapy.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1468% match
“Our mission is to identify, acquire, and accelerate the development and commercialization of medicines that we believe have the potential to offer clinically meaningful, differentiated benefits to patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2868% match
“Our mission is to develop and commercialize proprietary therapeutic drug products that treat rare and orphan diseases, particularly for those diseases where no approved treatment currently exists.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2668% match
“Our mission is to solve unmet medical needs by commercializing discoveries from research universities and medical centers We are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and patient solutions.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-04-1168% match
“Our mission is to develop innovative products to address unmet medical needs and to improve the quality of life of our patients.”In use 2006 – now·1 sighting·SEC Form 20-F, filed 2006-02-2868% match
“Our mission is to become a leading fully-integrated pharmaceutical company delivering new medicines to patients with unmet medical needs.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-2868% match
“Our mission is to become a leading pharmaceutical company by pioneering Bicycle molecules as a novel therapeutic modality to treat diseases that are inadequately addressed with existing treatment modalities.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1768% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2168% match
“Our mission is to enable anyone and any company to use our integrated open-access drug discovery and development platform to discover and develop new therapeutic products to benefit patients worldwide.”In use 2015 – now·1 sighting·SEC Form 20-F, filed 2015-04-1568% match
“Our mission is to leverage unique insights into protein motion to transform the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of small molecule therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions.”In use 2015 – now·1 sighting·SEC Form S-1, filed 2015-07-2468% match
“Our mission is to discover and develop best- and first-in-class medicines for a broad range of difficult-to-treat diseases in collaboration with our partners.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-04-0868% match
“Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2367% match
“Our mission is to discover and develop broadly accessible oral therapeutics to treat a wide range of chronic diseases with unmet medical need through advancements in structure-based drug discovery and computational chemistry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to leverage our unique insights into finding and binding cryptic functional pockets on currently intractable human biology-validated protein targets to discover, develop and commercialize small molecule therapies that can transform the lives of patients suffering from devastating cancers and immune disorders.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-06-2567% match
“Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3167% match
“Our mission is to improve patients’ lives by identifying, developing and commercializing products that address unmet medical needs.”In use 2013 – now·1 sighting·SEC Form 10-K, filed 2013-02-2667% match
“Our mission is to provide access to high-quality, innovative, impactful, and affordable medicines to billions more people globally.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-02-2567% match
“Our mission is to create safe and effective oral medicines to engage novel targets in therapeutic areas of unmet medical need where current treatments have limited efficacy or safety and tolerability concerns.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2167% match
“Our mission is to profitably accelerate drug discovery.”In use 2005 – now·1 sighting·SEC Form 10-K/A, filed 2005-04-2967% match
“Our mission is to create long-term stockholder value by acquiring, developing and commercializing innovative products for the treatment of a variety of human diseases that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment.”In use 2014 – now·1 sighting·SEC Form 10-K, filed 2014-03-1167% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2567% match
“Our mission is to transform the lives of patients with chronic IMIDs through the development of oral, safe and effective small molecule product candidates.”In use 2026 – now·1 sighting·SEC Form S-1/A, filed 2026-01-2767% match
“Our mission is to create and advance new medicines for patients suffering from serious and rare diseases that are underserved by today’s therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to provide drug and product developers with superior scientific research, high-quality research models and innovative analytical instrumentation in order to bring revolutionary new drugs and products to market quickly and safely.”In use 2021 – now·1 sighting·SEC Form S-1, filed 2021-12-2367% match
“Our mission is to translate complex, powerful biology with rigor and urgency into life-changing medicines.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1166% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2466% match
“Our mission is to develop and commercialize novel and best-in-class therapeutics to address unmet medical needs in the emerging otology market.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-03-1866% match
“Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2766% match
“Our mission is to make progress towards individualized medicine allowing development of designer drugs for precise disease therapies and to produce drugs that are cost effective thus allowing the population at large to gain their benefits.”In use 2008 – now·1 sighting·SEC Form 10-K, filed 2008-12-2466% match
“Our mission is to identify, develop, and, directly or through collaborations, bring to market novel products for the treatment of rare and ultra-rare diseases or conditions.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-1466% match
“Our mission is to translate our understanding of extracellular tRNA synthetase biology into novel first-in-class drug programs for conditions with unmet patient need.”In use 2018 – now·1 sighting·SEC Form 10-K, filed 2018-03-2066% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2866% match
“Our mission is to develop a portfolio of innovative product candidates for the treatment of cancer.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-02-0766% match
“Our mission is to maximize the clinical and commercial potential of cabozantinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-02-2266% match
“Our mission is to become a global leader in the treatment of rare diseases through commercializing, developing and acquiring novel rare disease products.”In use 2021 – now·1 sighting·SEC Form 424B4, filed 2021-01-1466% match
“Our mission is to improve the lives of patients by accelerating the development of our customers’ drugs and devices through innovative solutions.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-2766% match
Showing 1–50 of 50